Talphera, Inc.
$0.78
▼
-7.12%
2026-04-21 09:50:00
talphera.com
NCM: TLPH
Explore Talphera, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$40.17 M
Current Price
$0.78
52W High / Low
$1.57 / $0.38
Stock P/E
—
Book Value
$0.34
Dividend Yield
—
ROCE
-52.04%
ROE
-1.15%
Face Value
—
EPS
$-0.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
12
Beta
0.56
Debt / Equity
38.15
Current Ratio
5.49
Quick Ratio
5.49
Forward P/E
-2.72
Price / Sales
1,359.57
Enterprise Value
$24.19 M
EV / EBITDA
—
EV / Revenue
863.78
Rating
None
Target Price
$3.25
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Citius Oncology, Inc. | $0.92 | — | $77.5 M | — | -45.72% | -47.41% | $6.19 / $0.49 | $0.69 |
| 2. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 3. | Perrigo Company plc | $12.04 | — | $1.66 B | 9.63% | 4.16% | -38.66% | $28.43 / $9.22 | $21.33 |
| 4. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 5. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
| 6. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
| 7. | Lantheus Holdings, Inc. | $83.97 | 23.41 | $5.47 B | — | 16.66% | 21.45% | $108.91 / $47.25 | $16.87 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.03 M | 0 M | — |
| Operating Profit | -3.45 M | -3.42 M | -3.69 M | -2.92 M | -3 M | — |
| Net Profit | -3.77 M | -4.44 M | -3.49 M | -2.59 M | -1.87 M | — |
| EPS in Rs | -0.08 | -0.09 | -0.07 | -0.05 | -0.04 | -0.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.03 M | 0 M | 0.65 M | 0 M |
| Operating Profit | -13.48 M | -15.25 M | -16.89 M | -20.35 M |
| Net Profit | -14.29 M | -13 M | -18.4 M | 47.76 M |
| EPS in Rs | -0.29 | -0.26 | -0.37 | 0.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 29.72 M | 18.24 M | 20.39 M | 47.49 M |
| Total Liabilities | 12.68 M | 10.23 M | 6.29 M | 25.67 M |
| Equity | 17.04 M | 8 M | 14.11 M | 21.81 M |
| Current Assets | 20.9 M | 9.42 M | 11.58 M | 24.57 M |
| Current Liabilities | 3.81 M | 2.65 M | 4.51 M | 13.77 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -11.36 M | -12.68 M | -17.49 M | -28.33 M |
| Investing CF | -14.35 M | 3.78 M | -0.53 M | 36.45 M |
| Financing CF | 22.74 M | 12.04 M | 3.47 M | -0.51 M |
| Free CF | -11.36 M | -12.68 M | -17.59 M | -28.7 M |
| Capex | — | — | -0.1 M | -0.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | — | — |
| Earnings Growth % | 29.31% | -138.52% | — | — |
| Profit Margin % | — | -2825.96% | — | — |
| Operating Margin % | — | -2594.32% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -1511.83% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-10-26 | 1:0.05 |